ArticleBritish journal of haematology2019

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Andrzej J Jakubowiak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.